We agreed to meet again, some time in July. They were, in marked contrast to Eli Lilly and Company, in no hurry to get it done. But finally they did. When we spoke, on November 25, Mr. Hedin said he'd like to shoot for about January 13. He repeated that he had a lot to do, but said the meeting looked like it would happen perhaps the first week in March.
Questions remain unanswered.
Although Eli Lilly and Company, once persuaded, did complete their research in a timely manner, Novo Nordisk's repeated delays seem to me those of a company preoccupied with market share, industrial politics, and sheer organizational inertia. This is my opinion. By statute, the Food and Drug Administration is charged with the responsibility of protecting the health of all U.S. citizens. When presented with the specifics, the FDA must act. It is their job.